BOM:543635

Piramal Pharma Gets US FDA's Establishment Inspection Report for Digwal, India, Unit

Piramal Pharma (NSE:PPLPHARMA, BOM:543635) has received an establishment inspection report from the US Food and Drug Administration (US FDA) after the inspection of its manufacturing facility at Digwal in Telangana, India, according to a filing to the Indian stock exchanges on Monday.With this, the inspection has been successfully closed by the US FDA.The company's shares were down nearly 1% in recent trade.

Jefferies Adjusts Piramal Pharma's Price Target to INR190 from INR210, Keeps at Buy

Piramal Pharma Swings to Consolidated Loss in Fiscal Q4

Piramal Pharma (NSE:PPLPHARMA, BOM:543635) swung to an attributable consolidated loss of 88.2 million Indian rupees in the fiscal fourth quarter ended March 31 from a profit of 1.54 billion rupees a year ago.Loss per share came in at 0.07 rupees from earnings per share of 1.16 rupees a year earlier, the pharmaceutical company said in a filing to the Indian stock exchanges on Tuesday.Revenue from operations in fiscal Q4 stood at 27.5 billion rupees, almost unchanged from a year ago.Shares of the company fell nearly 1% in recent trade.

Piramal Pharma's Lexiton Facility Gets 'Voluntary Action Indicated' Classification from US FDA

Piramal Pharma (NSE:PPLPHARMA, BOM:543635) has received the establishment inspection report (EIR) with 'voluntary action indicated' classification from the U.S. Food and Drug Administration (US FDA) for its manufacturing facility in Lexington, India, according to a Monday filing to the Indian stock exchanges.The FDA conducted a general good manufacturing practices (GMP) inspection of the Lexington facility from Dec. 3, 2025, to Dec. 10, 2025. At the conclusion of the inspection, the US FDA issued a Form-483, with four observations.The receipt of EIR marks the successful closure of the US FDA's inspection at Piramal Pharma's manufacturing unit in Lexington.The company's shares were up nearly 1% in recent trade.